January 2013 in “Journal of Chengdu Medical College” In this study, Tolterodine Tartrate significantly improved symptoms of overactive bladder and showed fewer adverse reactions compared to the control group treatment.
November 2007 in “Hospital pharmacy” This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.
April 2013 in “The Journal of Urology” Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.
January 2009 in “Side effects of drugs annual” This study observed no teratogenic effects of oral decongestants and surprisingly favorable neonatal outcomes in Swedish women who used them during pregnancy.
5 citations
,
May 2018 in “European journal of pharmacology” This study reviewed the pharmacological properties of fesoterodine and found that its ability to effectively treat overactive bladder, especially in the elderly, is likely due to its specific properties, including its receptor affinity, blood-brain barrier penetration, metabolic conversion, and extended-release formulation.